Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer.
| Title | Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer. |
| Publication Type | Journal Article |
| Year of Publication | 2020 |
| Authors | Sardeli, C., Zarogoulidis P., Romanidis K., Oikonomou P., Sapalidis K., Huang H., Bai C., Hohenforst-Schmidt W., Tsakiridis K., Zaric B., Perin B., Ioannidis A., Baka S., Drevelegas K., Kosmidou M., & Kosmidis C. |
| Journal | Respir Med Case Rep |
| Volume | 31 |
| Pagination | 101258 |
| Date Published | 2020 |
| ISSN | 2213-0071 |
| Abstract | Nowadays we have novel therapies for advanced stage non-small cell lung cancer. Immunotherapy has been introduced in the market for several years and until now its administration is mostly based on the programmed death-ligand 1. First line treatment with immunotherapy can be administered alone if programmed death-ligand 1 expression is ≥ 50%. All therapies for advanced stage disease have advantages and disadvantages, immunotherapy until now has presented mild adverse effects when compared to chemotherapy. However; it is known to induce inflammatory response to different tissues within the body. In our case acute pneumothorax was induced after immunotherapy administration. |
| DOI | 10.1016/j.rmcr.2020.101258 |
| Alternate Journal | Respir Med Case Rep |
| PubMed ID | 33145157 |
| PubMed Central ID | PMC7596337 |
